{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:23:52Z","timestamp":1780503832206,"version":"3.54.1"},"posted":{"date-parts":[[2025,2,17]]},"group-title":"In Review","reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,1,31]]},"abstract":"<title>Abstract<\/title>\n        <p>Background:\n In a healthy lung, the airway epithelium regulates glucose transport to maintain low glucose concentrations in the airway surface liquid (ASL). However, hyperglycemia and chronic lung diseases, such as cystic fibrosis (CF), can result in increased glucose in bronchial aspirates. People with CF are also at increased risk of lung infections caused by bacterial pathogens, including methicillin-resistant <italic>Staphylococcus aureus.<\/italic> Yet, it is not known how increased airway glucose availability affects bacteria in chronic CF lung infections or impacts treatment outcomes.\nMethods:\n To model the CF airways, we cultured immortalized CF (CFBE41o-) and non-CF (16HBE) human bronchial epithelial cells at air liquid interface (ALI). Glucose concentrations in the basolateral media were maintained at 5.5 mM or 12.5 mM, to mimic a normal and hyperglycemic milieu respectively. 2-deoxyglucose was added to high glucose culture media to restrict glucose availability. We collected ASL, basolateral media, and RNA from ALI cultures to assess the effects of elevated glucose. We also inoculated <italic>S. aureus<\/italic> onto the apical surface of normal or high glucose ALI cultures and observed the results of antibiotic treatment post-inoculation. <italic>S. aureus<\/italic> growth was measured by enumerating viable colony forming units (CFU) and with fluorescence microscopy. The effects of elevated glucose on <italic>in vitro<\/italic> growth and antibiotic treatment were also evaluated in standard bacterial culture medium and synthetic CF medium (SCFM).\nResults:\n We found that glucose concentrations in the ASL of ALI cultures maintained in normal or high glucose mimicked levels measured in breath condensate assays from people with CF and hyperglycemia. Additionally, we found hyperglycemia increased <italic>S. aureus<\/italic> aggregation and antibiotic resistance during infection of cells maintained in high glucose compared to normal glucose conditions. Heightened antibiotic tolerance or resistance as not observed during <italic>in vitro<\/italic> growth with elevated glucose. Limiting glucose with 2-deoxyglucose both decreased aggregation and reduced antibiotic resistance back to levels comparable to non-hyperglycemic conditions.\nConclusions:\n These data indicate hyperglycemia alters <italic>S. aureus<\/italic> growth during infection and may reduce efficacy of antibiotic treatment. Glucose restriction is a potential option that could be explored to limit bacterial growth and improve treatment outcomes in chronic airway infections.<\/p>","DOI":"10.21203\/rs.3.rs-5938603\/v1","type":"posted-content","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T06:50:28Z","timestamp":1739775028000},"source":"Crossref","is-referenced-by-count":1,"title":["Elevated glucose increases methicillin-resistant Staphylococcus aureus antibiotic tolerance in a cystic fibrosis airway epithelial cell infection model"],"prefix":"10.21203","author":[{"given":"Emily M.","family":"Hughes","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan J.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Huffines","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Krick","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Kiedrowski","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Steven M. Rowe, Stacey Miller, Eric J. Sorscher. 2005. Mechanisms of Disease: Cysitc Fibrosis. New England Journal of Medicine 352.","DOI":"10.1056\/NEJMra043184"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. Livraghi A, Randell SH. 2007. Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance. Toxicol Pathol 35:116\u2013129.","DOI":"10.1080\/01926230601060025"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Lyczak JB, Cannon CL, Pier GB. 2002. Lung Infections Associated with Cystic Fibrosis. Clin Microbiol Rev 15:194\u2013222.","DOI":"10.1128\/CMR.15.2.194-222.2002"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Kayani K, Mohammed R, Mohiaddin H. 2018. Cystic Fibrosis-Related Diabetes. Front Endocrinol 9:20.","DOI":"10.3389\/fendo.2018.00020"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R. 2019. Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. Journal of Cystic Fibrosis 18:S3\u2013S9.","DOI":"10.1016\/j.jcf.2019.08.016"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Hart NJ, Aramandla R, Poffenberger G, Fayolle C, Thames AH, Bautista A, Spigelman AF, Babon JAB, DeNicola ME, Dadi PK, Bush WS, Balamurugan AN, Brissova M, Dai C, Prasad N, Bottino R, Jacobson DA, Drumm ML, Kent SC, MacDonald PE, Powers AC. 2018. Cystic fibrosis\u2013related diabetes is caused by islet loss and inflammation. JCI Insight 3:e98240.","DOI":"10.1172\/jci.insight.98240"},{"key":"ref7","unstructured":"7. Cystic Fibrosis Foundation Patient Registry. 2023. 2023 Annual Data Report."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM. 2015. Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor. Clinical Infectious Diseases 60:703\u2013712.","DOI":"10.1093\/cid\/ciu944"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Dalfsen JM, Singh SBP, Ni W, Hoffman LR, McGeer K, Heltshe SL, Clancy JP, Rowe SM, Jorth P, Singh PK. 2023. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. Journal of Clinical Investigation 133:e167957.","DOI":"10.1172\/JCI167957"},{"key":"ref10","unstructured":"10. Raygada JL, Levine DP. 2009. Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community. AMERICAN HEALTH 2."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Dasenbrook EC. 2010. Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis. JAMA 303:2386.","DOI":"10.1001\/jama.2010.791"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Philips BJ. 2005. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax 60:761\u2013764.","DOI":"10.1136\/thx.2004.035766"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Gill SK, Hui K, Farne H, Garnett JP, Baines DL, Moore LSP, Holmes AH, Filloux A, Tregoning JS. 2016. Increased airway glucose increases airway bacterial load in hyperglycaemia. Sci Rep 6:27636.","DOI":"10.1038\/srep27636"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. 2013. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 13:268.","DOI":"10.1186\/1471-2334-13-268"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. 2020. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. Journal of Cystic Fibrosis 19:68\u201379.","DOI":"10.1016\/j.jcf.2019.05.015"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Onady GM, Stolfi A. 2020. Drug treatments for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2020.","DOI":"10.1002\/14651858.CD004730.pub5"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Ode KL, Chan CL, Granados A, Moheet A, Moran A, Brennan AL. 2019. Cystic fibrosis related diabetes: Medical management. Journal of Cystic Fibrosis 18:S10\u2013S18.","DOI":"10.1016\/j.jcf.2019.08.003"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Jennings MT, Dasenbrook EC, Lechtzin N, Boyle MP, Merlo CA. 2017. Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Journal of Cystic Fibrosis 16:681\u2013686.","DOI":"10.1016\/j.jcf.2017.04.010"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Zemke AC, Nouraie SM, Moore J, Gaston JR, Rowan NR, Pilewski JM, Bomberger JM, Lee SE. 2019. Clinical predictors of cystic fibrosis chronic rhinosinusitis severity. Int Forum Allergy Rhinol 9:759\u2013765.","DOI":"10.1002\/alr.22332"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Garnett JP, Baker EH, Baines DL. 2012. Sweet talk: insights into the nature and importance of glucose transport in lung epithelium. Eur Respir J 40:1269\u20131276.","DOI":"10.1183\/09031936.00052612"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME, Philips BJ, Baines DL, Wood DM. 2007. Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. Journal of Applied Physiology 102:1969\u20131975.","DOI":"10.1152\/japplphysiol.01425.2006"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Baker EH. 2006. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61:284\u2013289.","DOI":"10.1136\/thx.2005.051029"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Mallia P, Webber J, Gill SK, Trujillo-Torralbo M-B, Calderazzo MA, Finney L, Bakhsoliani E, Farne H, Singanayagam A, Footitt J, Hewitt R, Kebadze T, Aniscenko J, Padmanaban V, Molyneaux PL, Adcock IM, Barnes PJ, Ito K, Elkin SL, Kon OM, Cookson WO, Moffat MF, Johnston SL, Tregoning JS. 2018. Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology 142:815\u2013823.e6.","DOI":"10.1016\/j.jaci.2017.10.017"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. Kiedrowski MR, Gaston JR, Kocak BR, Coburn SL, Lee S, Pilewski JM, Myerburg MM, Bomberger JM. 2018. Staphylococcus aureus Biofilm Growth on Cystic Fibrosis Airway Epithelial Cells Is Enhanced during Respiratory Syncytial Virus Coinfection. mSphere 3.","DOI":"10.1128\/mSphere.00341-18"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Malone CL, Boles BR, Lauderdale KJ, Thoendel M, Kavanaugh JS, Horswill AR. 2009. Fluorescent reporters for Staphylococcus aureus. Journal of Microbiological Methods 77:251\u2013260.","DOI":"10.1016\/j.mimet.2009.02.011"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Palmer KL, Aye LM, Whiteley M. 2007. Nutritional Cues Control Pseudomonas aeruginosa Multicellular Behavior in Cystic Fibrosis Sputum. J Bacteriol 189:8079\u20138087.","DOI":"10.1128\/JB.01138-07"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Rowe SE, Wagner NJ, Li L, Beam JE, Wilkinson AD, Radlinski LC, Zhang Q, Miao EA, Conlon BP. 2020. Reactive oxygen species induce antibiotic tolerance during systemic Staphylococcus aureus infection. Nat Microbiol 5:282\u2013290.","DOI":"10.1038\/s41564-019-0627-y"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Armbruster CR, Li K, Kiedrowski MR, Zemke AC, Melvin JA, Moore J, Atteih S, Fitch AC, DuPont M, Manko CD, Weaver ML, Gaston JR, Alcorn JF, Morris A, Meth\u00e9 BA, Lee SE, Bomberger JM. 2022. Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis. Microbiol Spectr 10:e01251-22.","DOI":"10.1128\/spectrum.01251-22"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Bjarnsholt T, Jensen P\u00d8, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, H\u00f8iby N. 2009. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatric Pulmonology 44:547\u2013558.","DOI":"10.1002\/ppul.21011"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Hirsch MJ, Hughes EM, Easter MM, Bollenbecker SE, Howze Iv PH, Birket SE, Barnes JW, Kiedrowski MR, Krick S. 2023. A novel in vitro model to study prolonged Pseudomonas aeruginosa infection in the cystic fibrosis bronchial epithelium. PLoS ONE 18:e0288002.","DOI":"10.1371\/journal.pone.0288002"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Pajak B, Siwiak E, So\u0142tyka M, Priebe A, Zieli\u0144ski R, Fokt I, Ziemniak M, Ja\u015bkiewicz A, Borowski R, Domoradzki T, Priebe W. 2019. 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents. IJMS 21:234.","DOI":"10.3390\/ijms21010234"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. 2004. Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises. Diabetes 53:2079\u20132086.","DOI":"10.2337\/diabetes.53.8.2079"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis G-A, Vogiatzi G, Papaioannou S, Deftereos S, Tousoulis D. 2019. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol 14:50\u201359.","DOI":"10.15420\/ecr.2018.33.1"},{"key":"ref34","unstructured":"34. Osika E, Cavaillon J-M, Chadelat K, Boule M, Fitting C, Tournier G, Clement A. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease 8."},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Goldstein BP. 2014. Resistance to rifampicin: a review. J Antibiot 67:625\u2013630.","DOI":"10.1038\/ja.2014.107"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"36. Bengtson CD, Kim MD, Anabtawi A, He J, Dennis JS, Miller S, Yoshida M, Baumlin N, Salathe M. 2020. Hyperglycaemia in CF adversely affects BK channel function critical for mucus clearance. Eur Respir J 2000509.","DOI":"10.1183\/13993003.00509-2020"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37. Vazquez Cegla AJ, Jones KT, Cui G, Cottrill KA, Koval M, McCarty NA. 2024. Effects of hyperglycemia on airway epithelial barrier function in WT and CF 16HBE cells. Sci Rep 14:25095.","DOI":"10.1038\/s41598-024-76526-3"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"38. Regassa LB, Novick RP, Betley MJ. 1992. Glucose and nonmaintained pH decrease expression of the accessory gene regulator (agr) in Staphylococcus aureus. Infect Immun 60:3381\u20133388.","DOI":"10.1128\/iai.60.8.3381-3388.1992"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"39. Boles BR, Horswill AR. 2008. agr-Mediated Dispersal of Staphylococcus aureus Biofilms. PLoS Pathog 4:e1000052.","DOI":"10.1371\/journal.ppat.1000052"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"40. Weinrick B, Dunman PM, McAleese F, Murphy E, Projan SJ, Fang Y, Novick RP. 2004. Effect of Mild Acid on Gene Expression in Staphylococcus aureus. J Bacteriol 186:8407\u20138423.","DOI":"10.1128\/JB.186.24.8407-8423.2004"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-5938603\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-5938603\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T06:50:46Z","timestamp":1739775046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-5938603\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":40,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-5938603\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,2,17]]},"subtype":"preprint"}}